[Metoclopramide plasma levels following oral administration of high doses for prophylaxis of emesis in cytostatic therapy].
To investigate the effectiveness of high oral doses of the antiemetic agent 4-amino-5-chloro-N-(2-diethyl-aminoethyl)-2-methoxybenzamide (metoclopramide, MCP, Gastrosil) against nausea and vomiting induced by certain cyostatic drugs, blood was withdrawn repeatedly from 9 patients; MCP plasma levels were then determined. Patients received 3 X 50 mg MCP-hydrochloride tablets in intervals of 4 h. Plasma levels determined from 7 patients were as follows: 173 ng/ml 1 h following the first dose of MCP 235 ng/ml 1 h following the second dose and finally 265 ng/ml following the third dose. Using the oral MCP dosage regimen presented in this study, high and relatively constant MCP plasma concentrations without undesired peak levels could be achieved.
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D008787:Metoclopramide / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000970:Antineoplastic Agents; D008787:Metoclopramide
Metoclopramid-Plasmaspiegel nach oraler Gabe hoher Dosen zur Emesisprophylaxe bei zytostatischer Therapie.